Feature

Head to head

Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No

BMJ 2007; 334 doi: 10.1136/bmj.39202.397488.AD (Published 10 May 2007)
Cite this as: BMJ 2007;334:983

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Malcolm Kendrick, general practitioner
  1. 24 Prestwick Close, Tytherington, Macclesfield, Cheshire SK10 2TH
  1. malcolmken{at}doctors.org.uk

    Women in western countries are more likely to die from heart disease than from cancer. Scott M Grundy argues that the risks make preventive treatment essential, but Malcolm Kendrick believes the evidence of benefit is not strong enough

    As no other cholesterol lowering drug has been shown to improve survival, this discussion is effectively about the use of statins. To date, none of the large trials of secondary prevention with statins has shown a reduction in overall mortality in women.1 Perhaps more critically, the primary prevention trials have shown neither an overall mortality benefit, nor even a reduction in cardiovascular end points in women.2 This raises the important question whether women should be prescribed statins at all.

    I believe that the answer is clearly no. Not only do statins fail to provide any overall health benefit in women, they represent a massive financial drain on health services. This money could be diverted to treatments of proved value.

    In addition to the lack of benefit and expense, statins …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular